Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:abuseDeterrentMechanism |
viscous gel formulation
|
| gptkbp:activeIngredient |
gptkb:oxycodone
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2018)
|
| gptkbp:countryOfOrigin |
gptkb:United_States
|
| gptkbp:designedFor |
abuse deterrence
|
| gptkbp:developer |
gptkb:Pfizer
gptkb:King_Pharmaceuticals gptkb:Pain_Therapeutics gptkb:Durect_Corporation |
| gptkbp:drugClass |
opioid
|
| gptkbp:firstNDAFiled |
2008
|
| gptkbp:form |
gptkb:extended-release_oxycodone
|
| https://www.w3.org/2000/01/rdf-schema#label |
Remoxy
|
| gptkbp:intendedUse |
pain management
|
| gptkbp:lastNDAResubmission |
2018
|
| gptkbp:market |
not marketed
|
| gptkbp:regulates |
not approved
NDA resubmitted multiple times |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:Pain_Therapeutics
|
| gptkbp:bfsLayer |
7
|